Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Novel Immunoassay Developed for Prostate Cancer

By LabMedica International staff writers
Posted on 26 May 2011
A blood test that uses proximity ligation (PLA) techniques has been applied as an innovative method for diagnosing prostate cancer. More...


The proximity ligation technique is uniquely specific and effective in the determination of proteins and the method has now been adapted for detecting abnormal levels of nanometer-sized vesicles called prostasomes.

Scientists at the University of Uppsala (Sweden) created monoclonal antibodies to recognize simultaneously proteins on the surface of the prostasomes, and this allowed them to detect elevated levels of prostasomes in the blood of patients with prostate cancer. The assay, called the 4PLA, detects complex target structures such as microvesicles in which the target is first captured via an immobilized antibody and subsequently detected by using four other antibodies with attached DNA strands.

Blood plasma was obtained from two groups of patients with prostate cancer and compared with age-matched controls. In a second group, samples from 59 patients, aged 53-73 years, whose Prostate Secreted Antigen (PSA) test results were between 1.1 ng/mL - 39.1 ng/mL, were compared with 20 age-matched controls with benign results from transrectal ultrasound-guided biopsies, aged 53-75 years, whose PSA test results were between 1.7 ng/mL - 14.8 ng/mL.

The assay successfully detected significantly elevated levels of prostasomes in blood samples from patients with prostate cancer before radical prostatectomy, as compared with controls and men with benign biopsy results. The medians for prostasome levels in blood plasma of patients with prostate cancer were from 2.5 to 7-fold higher compared with control samples in two independent studies. The assay also distinguished patients with high and medium prostatectomy Gleason scores (8/9 and 7, respectively) from those with low score, equal to or less than 6, thus reflecting disease aggressiveness. The approach that enables detection of prostasomes in peripheral blood may be useful for early diagnosis and assessment of prognosis in organ-confined prostate cancer.

Proximity ligation technology used in this study is commercialized by Olink Bioscience (Uppsala, Sweden). In the limited patient material examined in the study, blood levels of prostasomes seem to correlate more closely with the severity of the disease than do PSA levels. The authors of the study are hopeful that this type of biomarker will prove valuable not only for prostate cancer but also in several other common tumor types. The study was published on May 13, 2011, in the Proceedings of the National Academy of Sciences of the Unites States of America (PNAS).

Related Links:
University of Uppsala
Olink Bioscience



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.